Literature DB >> 10690885

Asp361Val Mutant of alkaline phosphatase found in patients with dominantly inherited hypophosphatasia inhibits the activity of the wild-type enzyme.

H L Müller1, M Yamazaki, T Michigami, T Kageyama, E Schönau, P Schneider, K Ozono.   

Abstract

Hypophosphatasia is characterized by the hypomineralization of bone associated with the mutation of the tissue-nonspecific alkaline phosphatase (TNSALP) gene. Although the disease is usually autosomal recessive, an autosomal dominant form is also recognized. Approximately 50 mutations have been found in the TNSALP gene in patients with hypophosphatasia. However, the mutations identified to date do not seem to account for the dominantly inherited form of the disease. We have examined a German family in which the father and all 4 children were affected with hypophosphatasia, whereas the mother was healthy. The affected members of this family showed premature loss of deciduous teeth at or shortly before 2 yr of age and low levels of serum ALP with elevated levels of urinary phosphoethanolamine. DNA analysis by direct sequencing revealed a heterozygous missense mutation that caused the conversion of amino acid Asp to Val at position 361 (D361V) in the patients. Another substitution was detected in exon 12 (Val to Ala conversion at codon 505: V505A) in 1 allele of the mother and 3 children, indicating no association of the substitution with the disease. Reconstruction experiments demonstrated that the D361V mutant protein lost its enzymatic activity and that it inhibited the function of wild-type enzyme when coexpressed in COS-7 cells. On the other hand, the V505A mutant exhibited enzymatic activities equal to those of the wild-type ALP. It is likely that the mutant D361V protein forms dimers with the wild-type protein, and the protein-protein interaction contributes to the dominant effect of the mutant D361V. The mutation that causes D361V is the first one proven to be associated with the dominant form of hypophosphatasia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690885     DOI: 10.1210/jcem.85.2.6373

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Clinical utility gene card for: hypophosphatasia.

Authors:  Etienne Mornet; Christine Beck; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2010-10-27       Impact factor: 4.246

2.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

3.  Retention at the cis-Golgi and delayed degradation of tissue-non-specific alkaline phosphatase with an Asn153-->Asp substitution, a cause of perinatal hypophosphatasia.

Authors:  Masahiro Ito; Norio Amizuka; Hidehiro Ozawa; Kimimitsu Oda
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

4.  Genetic analysis of adults heterozygous for ALPL mutations.

Authors:  Agnès Taillandier; Christelle Domingues; Annika Dufour; Françoise Debiais; Pascal Guggenbuhl; Christian Roux; Catherine Cormier; Bernard Cortet; Valérie Porquet-Bordes; Fabienne Coury; David Geneviève; Jean Chiesa; Thierry Colin; Elaine Fletcher; Agnès Guichet; Rose-Marie Javier; Michel Laroche; Michael Laurent; Ekkehart Lausch; Bruno LeHeup; Cédric Lukas; Georg Schwabe; Ineke van der Burgt; Christine Muti; Brigitte Simon-Bouy; Etienne Mornet
Journal:  J Bone Miner Metab       Date:  2017-12-13       Impact factor: 2.626

5.  Common mutations F310L and T1559del in the tissue-nonspecific alkaline phosphatase gene are related to distinct phenotypes in Japanese patients with hypophosphatasia.

Authors:  Toshimi Michigami; Takayuki Uchihashi; Akira Suzuki; Kanako Tachikawa; Shigeo Nakajima; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2005-01-20       Impact factor: 3.183

6.  Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Authors:  Lothar Seefried; Jasmin Baumann; Sarah Hemsley; Christine Hofmann; Erdmute Kunstmann; Beate Kiese; Yue Huang; Simon Chivers; Marie-Anne Valentin; Babul Borah; Ronenn Roubenoff; Uwe Junker; Franz Jakob
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

7.  A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein.

Authors:  A S Lia-Baldini; I Brun-Heath; C Carrion; B Simon-Bouy; J L Serre; M E Nunes; E Mornet
Journal:  Hum Genet       Date:  2008-03-14       Impact factor: 4.132

Review 8.  Alkaline phosphatase: an overview.

Authors:  Ujjawal Sharma; Deeksha Pal; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2013-11-26

Review 9.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

10.  Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles.

Authors:  Delphine Fauvert; Isabelle Brun-Heath; Anne-Sophie Lia-Baldini; Linda Bellazi; Agnès Taillandier; Jean-Louis Serre; Philippe de Mazancourt; Etienne Mornet
Journal:  BMC Med Genet       Date:  2009-06-06       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.